Geode Capital Management’s BioRestorative Therapies BRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding BRTX
HF
XT
WA
KFGK
Geode Capital Management's BRTX Position: Q2 2026 in Review
Geode Capital Management reduced its BioRestorative Therapies (BRTX) stake by 32% in Q2 2026, selling an estimated $20.7K and leaving 152,417 shares worth $57.3K. The position accounts for ﹤0.01% of the portfolio, ranked #4216.
Geode Capital Management first reported a position in BRTX in Q1 2022 and has held it in 18 quarters since. The position peaked at $193K in Q2 2023. 21 funds tracked by Wall St. Rank hold BRTX as of Q2 2026.
- Geode Capital Management held 152,417 shares of BioRestorative Therapies worth $57.3K as of Q2 2026.
- Geode Capital Management sold 70,666 BioRestorative Therapies shares in Q2 2026, an estimated $20.7K.
- BioRestorative Therapies made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #4216 holding.
- Geode Capital Management first reported a position in BioRestorative Therapies in Q1 2022 and has held it in 18 quarters since.
- Geode Capital Management's BioRestorative Therapies position peaked at $193K in Q2 2023.
- 21 funds tracked by Wall St. Rank held BioRestorative Therapies as of Q2 2026.
Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.